CFDE Data Portal | Search LOC100422398

	Label	Description
	LOC100422398 Gene (Entity type)	ENSG00000254877 - protein kinase cAMP-dependent type II regulatory subunit beta pseudogene
	GSE195663 cisplatin 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 9 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207376 GSE207377 nutlin-3 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178267 vemurafenib 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172494 nicotinamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Testis 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Esophagus 20-29 vs 30-39 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Bladder 20-29 vs 50-59 Up Gene Set (Entity type)	A Gene Set from GTEx

LOC100422398

ENSG00000254877 - protein kinase cAMP-dependent type II regulatory subunit beta pseudogene

GSE195663 cisplatin 0 v 3 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 9 v 4 human dn

A Gene Set from LINCS

GSE207376 GSE207377 nutlin-3 0 v 1 human dn

A Gene Set from LINCS

GSE178267 vemurafenib 2 v 0 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human dn

A Gene Set from LINCS

GSE172494 nicotinamide 2 v 1 human dn

A Gene Set from LINCS

GTEx Testis 20-29 vs 30-39 Up

A Gene Set from GTEx

GTEx Esophagus 20-29 vs 30-39 Down

A Gene Set from GTEx

GTEx Bladder 20-29 vs 50-59 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.